RxDoctor Payments Data

Marcus Malone, MD

Physical Medicine & Rehabilitation · Vero Beach, FLNPI 1437374683

Payments from drug & device makers

$1,658in general payments, 2019–2025

Across 68 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$232
  • Amgen$215
  • Sunovion Pharmaceuticals Inc.$179
  • Collegium Pharmaceutical, Inc.$172
  • Biodelivery Sciences International, Inc.$141
  • Saluda Medical Americas, Inc.$123
  • plus $596 from 16 others

What the payments were for

  • Food & beverage$1,658100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,658 in reported general payments places this provider in the 80th percentile of 618 physical medicine & rehabilitation providers in Florida.

See all physical medicine & rehabilitation providers in Florida

Medicare billing

Part B allowed, 2024
$786,789
Medicare patients
1,357
Services billed
9,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl266$236,717
Xtampza ErOxycodone Myristate197$88,691
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,146$48,713
Oxycodone Hcl1,894$47,912
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,363$35,188
Morphine Sulfate ErMorphine Sulfate662$31,964
Fentanyl267$28,976
Gabapentin738$11,360
LinzessLinaclotide17$10,262
Pregabalin297$8,710
Tramadol Hcl782$8,170
Nucynta ErTapentadol Hcl12$7,570
MovantikNaloxegol Oxalate17$6,883
Morphine Sulfate179$6,287
Hydromorphone Hcl164$6,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er$172$96,261209 claims
Redhill Biopharma Inc.Movantik$38$6,88317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 618 physical medicine & rehabilitation providers in Florida.

Other physical medicine & rehabilitation in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →